Trial · NCT00842530
Results by group330
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 330
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Symptomatic Virologically-Confirmed Dengue (VCD) Cases During the Active Phase Post-dose 3 Following Inj. With Either CYD Dengue Vaccine or a Placebo | CYD Dengue Vaccine Group | 45 | Cases | ||
| Number of Symptomatic Virologically-Confirmed Dengue (VCD) Cases During the Active Phase Post-dose 3 Following Inj. With Either CYD Dengue Vaccine or a Placebo | Control Group | 32 | Cases | ||
| Number of Severe VCD Cases During the Active Phase Post-dose 3 Following Inj. With Either CYD Dengue Vaccine or a Placebo | CYD Dengue Vaccine Group | Severe VCD cases (IDMC clinical assessment) | 1 | Cases | |
| Number of Severe VCD Cases During the Active Phase Post-dose 3 Following Inj. With Either CYD Dengue Vaccine or a Placebo | Control Group | Severe VCD cases (IDMC clinical assessment) | 2 | Cases | |
| Number of Severe VCD Cases During the Active Phase Post-dose 3 Following Inj. With Either CYD Dengue Vaccine or a Placebo | CYD Dengue Vaccine Group | Severe VCD cases (WHO 1999 severity assessment) | 2 | Cases | |
| Number of Severe VCD Cases During the Active Phase Post-dose 3 Following Inj. With Either CYD Dengue Vaccine or a Placebo | Control Group | Severe VCD cases (WHO 1999 severity assessment) | 2 | Cases | |
| Number of Symptomatic VCD Cases During the Active Phase Following at Least Two Inj. With Either CYD Dengue Vaccine or a Placebo | CYD Dengue Vaccine Group | Cases: 28 days Post-Inj. 2 up to Inj. 3 | 14 | Cases | |
| Number of Symptomatic VCD Cases During the Active Phase Following at Least Two Inj. With Either CYD Dengue Vaccine or a Placebo | Control Group | Cases: 28 days Post-Inj. 2 up to Inj. 3 | 12 | Cases | |
| Number of Symptomatic VCD Cases During the Active Phase Following at Least Two Inj. With Either CYD Dengue Vaccine or a Placebo | CYD Dengue Vaccine Group | Cases:28 days Post-Inj. 2 upto end of Active Phase | 61 | Cases | |
| Number of Symptomatic VCD Cases During the Active Phase Following at Least Two Inj. With Either CYD Dengue Vaccine or a Placebo | Control Group | Cases:28 days Post-Inj. 2 upto end of Active Phase | 47 | Cases | |
| Geometric Mean Titers (GMTs) of Antibodies Against Each Serotype With the Parental Dengue Virus Strain Before and Following Inj. With Either CYD Dengue Vaccine or a Placebo | CYD Dengue Vaccine Group | Dengue Virus Serotype 1; Pre-Inj. 1 | 42.8 | 95% Confidence Interval 30.7 to 59.6 | Titers (1/dilution) |
| Geometric Mean Titers (GMTs) of Antibodies Against Each Serotype With the Parental Dengue Virus Strain Before and Following Inj. With Either CYD Dengue Vaccine or a Placebo | Control Group | Dengue Virus Serotype 1; Pre-Inj. 1 | 26.6 | 95% Confidence Interval 17.6 to 40.2 | Titers (1/dilution) |
| Geometric Mean Titers (GMTs) of Antibodies Against Each Serotype With the Parental Dengue Virus Strain Before and Following Inj. With Either CYD Dengue Vaccine or a Placebo | CYD Dengue Vaccine Group | Dengue Virus Serotype 1; Post-Inj. 1 | 94.4 | 95% Confidence Interval 66.4 to 134 | Titers (1/dilution) |
| Geometric Mean Titers (GMTs) of Antibodies Against Each Serotype With the Parental Dengue Virus Strain Before and Following Inj. With Either CYD Dengue Vaccine or a Placebo | Control Group | Dengue Virus Serotype 1; Post-Inj. 1 | 27.7 | 95% Confidence Interval 18.1 to 42.3 | Titers (1/dilution) |
| Geometric Mean Titers (GMTs) of Antibodies Against Each Serotype With the Parental Dengue Virus Strain Before and Following Inj. With Either CYD Dengue Vaccine or a Placebo | CYD Dengue Vaccine Group | Dengue Virus Serotype 1; Pre-Inj. 2 | 78.0 | 95% Confidence Interval 54.4 to 112 | Titers (1/dilution) |
| Geometric Mean Titers (GMTs) of Antibodies Against Each Serotype With the Parental Dengue Virus Strain Before and Following Inj. With Either CYD Dengue Vaccine or a Placebo | Control Group | Dengue Virus Serotype 1; Pre-Inj. 2 | 30.5 | 95% Confidence Interval 19.8 to 47.1 | Titers (1/dilution) |
| Geometric Mean Titers (GMTs) of Antibodies Against Each Serotype With the Parental Dengue Virus Strain Before and Following Inj. With Either CYD Dengue Vaccine or a Placebo | CYD Dengue Vaccine Group | Dengue Virus Serotype 1; Post-Inj. 2 | 184 | 95% Confidence Interval 137 to 247 | Titers (1/dilution) |
| Geometric Mean Titers (GMTs) of Antibodies Against Each Serotype With the Parental Dengue Virus Strain Before and Following Inj. With Either CYD Dengue Vaccine or a Placebo | Control Group | Dengue Virus Serotype 1; Post-Inj. 2 | 28.3 | 95% Confidence Interval 18.2 to 43.8 | Titers (1/dilution) |
| Geometric Mean Titers (GMTs) of Antibodies Against Each Serotype With the Parental Dengue Virus Strain Before and Following Inj. With Either CYD Dengue Vaccine or a Placebo | CYD Dengue Vaccine Group | Dengue Virus Serotype 1; Pre-Inj. 3 | 116 | 95% Confidence Interval 84.8 to 160 | Titers (1/dilution) |
| Geometric Mean Titers (GMTs) of Antibodies Against Each Serotype With the Parental Dengue Virus Strain Before and Following Inj. With Either CYD Dengue Vaccine or a Placebo | Control Group | Dengue Virus Serotype 1; Pre-Inj. 3 | 26.4 | 95% Confidence Interval 17.1 to 40.8 | Titers (1/dilution) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00842530/results